Steve Jensen's questions to PROVECTUS BIOPHARMACEUTICALS (PVCT) leadership • Q2 2016
Question
Steve Jensen of Jensen Capital Management inquired about management's personal sentiment on the company's current status and also asked for details on the company's cash position and future financing plans.
Answer
Interim CEO, COO & CFO Peter Culpepper expressed strong personal conviction in the company's mission and the potential of its drug candidates, emphasizing a focus on perseverance to achieve success. CTO Eric Wachter added that from a technology standpoint, the company is in its strongest position ever. Regarding financing, Culpepper acknowledged the need to raise capital in the current quarter to continue operations until a non-dilutive partnership could be secured, stating confidence in obtaining funds from dedicated stockholders while minimizing dilution.